120 related articles for article (PubMed ID: 20843379)
1. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.
Bramlage P; Binz C; Gitt AK; Krekler M; Plate T; Deeg E; Tschöpe D
Cardiovasc Diabetol; 2010 Sep; 9():53. PubMed ID: 20843379
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
Herz; 2012 May; 37(3):294-300. PubMed ID: 22476616
[TBL] [Abstract][Full Text] [Related]
3. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
Int J Clin Pract; 2013 Oct; 67(10):1005-14. PubMed ID: 23981060
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: an analysis of the DiaRegis registry.
Gitt AK; Bramlage P; Binz C; Krekler M; Plate T; Deeg E; Tschöpe D;
Eur J Prev Cardiol; 2012 Aug; 19(4):765-72. PubMed ID: 21628353
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry.
Tschöpe D; Bramlage P; Binz C; Krekler M; Plate T; Deeg E; Gitt AK
Cardiovasc Diabetol; 2011 Jul; 10():66. PubMed ID: 21756359
[TBL] [Abstract][Full Text] [Related]
6. A real world comparison of sulfonylurea and insulin vs. incretin-based treatments in patients not controlled on prior metformin monotherapy.
Gitt AK; Bramlage P; Schneider S; Tschöpe D
Cardiovasc Diabetol; 2015 Feb; 14():13. PubMed ID: 25645672
[TBL] [Abstract][Full Text] [Related]
7. Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users.
Jensen MH; Kjolby M; Hejlesen O; Jakobsen PE; Vestergaard P
Diabetes Care; 2020 Jun; 43(6):1209-1218. PubMed ID: 32238426
[TBL] [Abstract][Full Text] [Related]
8. Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy--an analysis of the DiaRegis registry.
Wasem J; Bramlage P; Gitt AK; Binz C; Krekler M; Deeg E; Tschöpe D;
Cardiovasc Diabetol; 2013 Mar; 12():47. PubMed ID: 23510200
[TBL] [Abstract][Full Text] [Related]
9. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
10. Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up.
Bramlage P; Gitt AK; Schneider S; Deeg E; Tschöpe D;
BMC Cardiovasc Disord; 2014 Nov; 14():162. PubMed ID: 25410473
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
12. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
14. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
Asche CV; McAdam-Marx C; Shane-McWhorter L; Sheng X; Plauschinat CA
Drugs Aging; 2008; 25(7):611-22. PubMed ID: 18582148
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].
Sicras-Mainar A; Navarro-Artieda R
Rev Peru Med Exp Salud Publica; 2014; 31(4):626-34. PubMed ID: 25597711
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
[TBL] [Abstract][Full Text] [Related]
19. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
Matthaei S; Bowering K; Rohwedder K; Grohl A; Parikh S;
Diabetes Care; 2015 Mar; 38(3):365-72. PubMed ID: 25592197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
